Estrogen O-sulfamates and their analogues

clinical steroid sulfatase inhibitors with broad potential

Mark P. Thomas, Barry V. L. Potter

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Estrogen sulfamate derivatives were the first irreversible active-site-directed inhibitors of steroid sulfatase (STS), an emerging drug target for endocrine therapy of hormone dependent diseases that catalyzes inter alia the hydrolysis of estrone sulfate to estrone. In recent years this has stimulated clinical investigation of the estradiol derivative both as an oral prodrug and its currently ongoing exploration in endometriosis. 2-Substituted steroid sulfamate derivatives show considerable potential as multi-targeting agents for hormone-independent disease, but are also potent STS inhibitors. The steroidal template has spawned nonsteroidal STS inhibitors one of which, Irosustat, has been evaluated clinically in breast cancer, endometrial cancer and prostate cancer and there is potential for innovative dual-targeting approaches. This review surveys the role of estrogen sulfamates, their analogues and current status.

Original languageEnglish
Article number4391
Pages (from-to)160-169
Number of pages10
JournalJournal of Steroid Biochemistry and Molecular Biology
Volume153
Early online date2 Apr 2015
DOIs
Publication statusPublished - 1 Sep 2015

Fingerprint

Steryl-Sulfatase
Estrogens
Derivatives
Prostatic Neoplasms
Hormones
Estrone
Prodrugs
Endometriosis
Endometrial Neoplasms
Estradiol
Hydrolysis
Catalytic Domain
Steroids
Breast Neoplasms
Pharmaceutical Preparations
sulfamic acid
Therapeutics

Keywords

  • Cancer
  • Endocrine Therapy
  • Inhibitor
  • Sulfamates
  • Sulfatase
  • Synthesis

Cite this

@article{2062a564cda94f4588ce3bfa41e3313f,
title = "Estrogen O-sulfamates and their analogues: clinical steroid sulfatase inhibitors with broad potential",
abstract = "Estrogen sulfamate derivatives were the first irreversible active-site-directed inhibitors of steroid sulfatase (STS), an emerging drug target for endocrine therapy of hormone dependent diseases that catalyzes inter alia the hydrolysis of estrone sulfate to estrone. In recent years this has stimulated clinical investigation of the estradiol derivative both as an oral prodrug and its currently ongoing exploration in endometriosis. 2-Substituted steroid sulfamate derivatives show considerable potential as multi-targeting agents for hormone-independent disease, but are also potent STS inhibitors. The steroidal template has spawned nonsteroidal STS inhibitors one of which, Irosustat, has been evaluated clinically in breast cancer, endometrial cancer and prostate cancer and there is potential for innovative dual-targeting approaches. This review surveys the role of estrogen sulfamates, their analogues and current status.",
keywords = "Cancer, Endocrine Therapy, Inhibitor, Sulfamates, Sulfatase, Synthesis",
author = "Thomas, {Mark P.} and Potter, {Barry V. L.}",
year = "2015",
month = "9",
day = "1",
doi = "10.1016/j.jsbmb.2015.03.012",
language = "English",
volume = "153",
pages = "160--169",
journal = "Journal of Steroid Biochemistry and Molecular Biology",
issn = "0960-0760",
publisher = "Elsevier",

}

TY - JOUR

T1 - Estrogen O-sulfamates and their analogues

T2 - clinical steroid sulfatase inhibitors with broad potential

AU - Thomas, Mark P.

AU - Potter, Barry V. L.

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Estrogen sulfamate derivatives were the first irreversible active-site-directed inhibitors of steroid sulfatase (STS), an emerging drug target for endocrine therapy of hormone dependent diseases that catalyzes inter alia the hydrolysis of estrone sulfate to estrone. In recent years this has stimulated clinical investigation of the estradiol derivative both as an oral prodrug and its currently ongoing exploration in endometriosis. 2-Substituted steroid sulfamate derivatives show considerable potential as multi-targeting agents for hormone-independent disease, but are also potent STS inhibitors. The steroidal template has spawned nonsteroidal STS inhibitors one of which, Irosustat, has been evaluated clinically in breast cancer, endometrial cancer and prostate cancer and there is potential for innovative dual-targeting approaches. This review surveys the role of estrogen sulfamates, their analogues and current status.

AB - Estrogen sulfamate derivatives were the first irreversible active-site-directed inhibitors of steroid sulfatase (STS), an emerging drug target for endocrine therapy of hormone dependent diseases that catalyzes inter alia the hydrolysis of estrone sulfate to estrone. In recent years this has stimulated clinical investigation of the estradiol derivative both as an oral prodrug and its currently ongoing exploration in endometriosis. 2-Substituted steroid sulfamate derivatives show considerable potential as multi-targeting agents for hormone-independent disease, but are also potent STS inhibitors. The steroidal template has spawned nonsteroidal STS inhibitors one of which, Irosustat, has been evaluated clinically in breast cancer, endometrial cancer and prostate cancer and there is potential for innovative dual-targeting approaches. This review surveys the role of estrogen sulfamates, their analogues and current status.

KW - Cancer

KW - Endocrine Therapy

KW - Inhibitor

KW - Sulfamates

KW - Sulfatase

KW - Synthesis

UR - http://www.scopus.com/inward/record.url?scp=84941260021&partnerID=8YFLogxK

UR - http://dx.doi.org/10.1016/j.jsbmb.2015.03.012

U2 - 10.1016/j.jsbmb.2015.03.012

DO - 10.1016/j.jsbmb.2015.03.012

M3 - Article

VL - 153

SP - 160

EP - 169

JO - Journal of Steroid Biochemistry and Molecular Biology

JF - Journal of Steroid Biochemistry and Molecular Biology

SN - 0960-0760

M1 - 4391

ER -